Linezolid

International Journal of Clinical Practice

Volumn 55, Issue 1, 2001, Pages 59-63

  French, G ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; AVOPARCIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL DERIVATIVE; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; ERYTHROMYCIN; FUSIDATE SODIUM; FUSIDIC ACID; GLYCOPEPTIDE; KETOLIDE; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; METICILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN DERIVATIVE; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; PNEUMOCOCCAL INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 0035126128     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-1072.
2. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumonias: an overview. Clin Infect Dis 1992; 15: 77-83.
3. Schmitz FJ, Verhoef J, Fluit AC. Comparative activity of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates originating
4. from 20 European university hospitals. SENTRY Participants Group. Eiir J Clin Microbiol Infect Dis 1999;18: 450-453.
5. Laurichesse H, Grimaud O, Waight P. Pneumococcal bacteria and meningitis in England and Wales 1993 to 1995. Comm Dis Pub Health 1998; 1: 22-27.
6. Speller DCE. Johnson AP, James D, Marples RR. Resistance to methicillin and other antibiotics in Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 1997; 350: 323-325.
7. Johnson AP, James D. Continuing increase in invasive methicillin-resistant Staphylococcus aureus infections. Lancet 1997; 350: 1710.
8. Pfaller MA, Jones RN, Doern GV et al. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States. Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diax Microbiol Infect Dis 1999; 33: 283-297.
9. Jones ME, Schmilz FJ. Fluit AC et al. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group. Kur J Clin Microbiol Infect Ois 1999; 18: 403-408.
10. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemolher 1997; 40: 135-136.
11. Ploy M. Grc'land C, de Lumley L, Denis F. First isolates of vancomycin-intermcdiate Staphylococcus aureus in a French hospital. Lancet 1998:351: 1212.
12. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3: 46-65.
13. Archibald L, Phillips L, Monnet D et ai. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211-215.
14. Bates J. Epidemiology of vancomycin-resistant enterococci in the community and the relevance of farm animals to human infection. J Hasp Infect 1997;37: 89-101.
15. Standing Medical Advisory Committee (SMAC), Sub-group on antimicrobial resistance. The path of least resistance. Department of Health (UK), London.1998.
16. French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998;27(suppl 1): S75-S83.
17. Noble WC, Virani Z, Crée RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. F EMS Microbiol Lett 1992; 93: 195-198.
18. Cohen ML. Epidemiology of drug resistance: implications for a postantimicrobial era. Science 1992:257: 1050-1055.
19. Kunin CM. Resistance to antimicrobial drugs: a worldwide calamity. Ann Intern Met! 1993: 118: 557-566.
20. House of Lords Select Committee on Science and Technology. 7th report. Resistance to antibiotics. ISBN 0-10-478998-0. London 1998. htiji : I IwwH-.fda.ifOv/ohrms/dockets/ac/OO/back^rdl 3597blba.pdf
21. Moellcring RC. Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant entcrococcal infections. J Antimicrob Chemolher 1999: 44(suppl A): 25-30.
22. Ford C.Hamel J.Stapert D et al. Oxazolidinones: anew class of antimicrobials. Infect Med 1999: 16: 435-445.
23. Barbachyn MR. Brickner SJ, Gadwood RC et al. Design, synthesis, and evaluation of novel oxazolidinone antibacterial agents active against multidrug-resistant bacteria. Adv F.xptl Med Biol 1998: 456: 219-238.
24. Slee AM. Wuonola MA, McRipley RJ et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemolher 1987: 31: 1791 -1797.
25. Ford CW, Hamel JC. Wilson DM et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996:40: 1508-1513.
26. Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant grampositive bacterial infections. J Med Chem 1996; 39: 673-679.
27. Pharmacia and Upjohn. Zyvox (linezolid) brochure and slide presentation for the Anti-Infective Drug Products Advisory Committee Meeting of the PDA, 24 March 2000.
28. Zurenko CE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicroh Agents Chemother 1996; 40: 839-845.
29. Schaadt RD, Batts DH, Daley-Yates FT et al. Serum inhibitory tilers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diag Microbiol Infect Dis-1997; 28: 201-204.
30. Noskin GA, Siddiqui F, Stosor V et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycinresistant enterococci. Antimicrob Agentx Chemother 1999; 43: 2059-2062.
31. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000; 45: 225-230.
32. Wise R, Andrews JM, Boswcll FJ, Ashby JP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998:42: 721-728.
33. Biedenbach DJ, Jones RN. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. J Clin Microbiol 1997; 35: 3198-3202.
34. Shinabarger DL, Marotti KR, Murray RW et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132-2136.
35. Swaney SM. Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-3255.
36. Murray RW, Schaadt RD, Zurenko GE, Marotti KR. Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphvlococcus uurens cell-free transcription-translation assay. Antimicrob Agents Chemother 1998; 42: 947-950.
37. Pawsey SD. Daley-Yates FT, Wajszczuk CP et al. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration (abstract). In: Program and abstracts of the 1st European Congress of Chemotherapy. Glasgow. 1996.
38. Welshman IR, Stalker DJ. Wajszczuk CP. Assessment of absolute bioavailability of linezolid (abstract). Antiinfect Drugs Chemother 1998; 16(suppl): 54.
39. Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days (abstract). In: Proceedings of the 37th Interscience Conference on Antimicrobials Agents and Chemotherapy. 1997.
40. Brier ME. Stalker DJ. Aronoff GR et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis (abstract). In: Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999.
41. Cammarata SK, Wunderink RG, Hempsall KA et al. Efficacy of linezolid in patients with nosocomial pneumonia based on severity of illness as determined by baseline APACHE II score (abstract). In: Proceedings of the 40th Interscience Conference on Antimicrobial Agents and C'hcmotherapy, 2000.
42. Pharmacia and Upjohn. Data on file.
43. Hartman CS, Leach TS. Kaja RW et al. Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter phase III trial (abstract). In: Proceedings of the 4()th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000.
44. Willkc RJ, Li ZJ, Rittenhouse BE et cil. Linczolid's effects on early hospital discharge in hospitalized patients with complicated skin and soft tissue infections under varying rates of methicillin-rcsistant staphylococcus infection: analysis of results from two randomized clinical trials (abstract). In: Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000.
45. Bruss JB, Smith LG, Duvall SE et al. Safety and tolerance of linezolid: adverse events reported in phase III trials (abstract). In: Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000.
46. Batts DH. Linezolid clinical development program: end of Phase II results (abstract). In: Abstracts of 2nd European Congress of Chemotherapy, Hamburg, Germany. 10-13 May 1998.